Piper Jaffray Upgrades Cepheid; Other Analysts More Cautious | GenomeWeb

NEW YORK (GenomeWeb News) – On the heels of a reported 19 percent increase year over year in Cepheid's second-quarter revenues, investment bank Piper Jaffray today upgraded the molecular diagnostics company to Overweight.

In a research note, analyst William Quirk upgraded Cepheid from Neutral and increased the price target on its shares to $43 from $37.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.